COST-CONSEQUENCE ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS

被引：0
|
作者：
Cortesi, P. A. [1 ]
Castaman, G. [2 ]
Mantovani, L. G. [1 ]
机构：
[1] Univ Milano Bicocca, Monza, Italy
[2] Azienda Osped Univ Careggi, Florence, Italy
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRO40
引用
收藏
页码：S696 / S696
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Emicizumab for Prophylaxis in People with Severe Hemophilia A without Inhibitors
    Decker-Palmer, Marquita
    Lin, Chia-Wei
    Wilson, Michele
    McDade, Cheryl
    Bawa, Komal
    Kowal, Stacey
    Ravelo, Arliene
    Yu, Elaine
    Ko, Richard H.
    [J]. BLOOD, 2022, 140 : 13041 - 13042
  • [2] COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS
    Olasupo, O.
    Matino, D.
    Iorio, A.
    Blackhouse, G.
    Xie, F.
    Tarride, J. E.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S428 - S428
  • [3] Emicizumab Prophylaxis in Patients with Hemophilia. with and without Inhibitors
    Ebbert, Patrick T.
    Xavier, Frederico
    Seaman, Craig D.
    Ragni, Margaret V.
    [J]. BLOOD, 2019, 134
  • [4] Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
    Mahlangu, J.
    Oldenburg, J.
    Paz-Priel, I.
    Negrier, C.
    Niggli, M.
    Mancuso, M. E.
    Schmitt, C.
    Jimenez-Yuste, V.
    Kempton, C.
    Dhalluin, C.
    Callaghan, M. U.
    Bujan, W.
    Shima, M.
    Adamkewicz, J. I.
    Asikanius, E.
    Levy, G. G.
    Kruse-Jarres, R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (09): : 811 - 822
  • [5] ECONOMIC IMPACT OF EMICIZUMAB PROPHYLAXIS FOR HEMOPHILIA A WITH AND WITHOUT INHIBITORS
    Cortesi, P. A.
    Castaman, G.
    Mantovani, L. G.
    [J]. VALUE IN HEALTH, 2020, 23 : S699 - S699
  • [6] Emicizumab Prophylaxis in Hemophilia A with Inhibitors
    Aledort, Louis M.
    Ewenstein, Bruce M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (22): : 2193 - 2193
  • [7] Emicizumab Prophylaxis in Hemophilia A with Inhibitors
    Oldenburg, Johannes
    Mahlangu, Johnny N.
    Kim, Benjamin
    Schmitt, Christophe
    Callaghan, Michael U.
    Young, Guy
    Santagostino, Elena
    Kruse-Jarres, Rebecca
    Negrier, Claude
    Kessler, Craig
    Valente, Nancy
    Asikanius, Elina
    Levy, Gallia G.
    Windyga, Jerzy
    Shima, Midori
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 809 - 818
  • [8] RESOURCE CONSUMPTION ANALYSIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS ON PROPHYLAXIS WITH FVIII BEFORE SWITCHING TO EMICIZUMAB
    Giacomini, E.
    Leogrande, M.
    Motta, L.
    Tempre, R.
    Bendinelli, S.
    Degli Esposti, L.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S69 - S69
  • [9] Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis
    Zimowski, Karen L.
    Batsuli, Glaivy M.
    Reding, Mark T.
    Rana, Jatin
    Callaghan, Michael U.
    Tickle, Kelly
    Meeks, Shannon L.
    Sidonio, Robert F., Jr.
    [J]. BLOOD, 2018, 132
  • [10] EMICIZUMAB PROPHYLAXIS IS A COST-SAVING OPTION FOR HEMOPHILIA A PATIENTS WITH INHIBITORS IN KOREA: A COST-EFFECTIVENESS ANALYSIS
    Lee, H.
    Cho, H.
    Han, J. W.
    Kim, A.
    Park, S.
    Lee, M.
    Cho, S.
    Baik, D.
    Kang, H. Y.
    [J]. VALUE IN HEALTH, 2019, 22 : S849 - S849
12345